Patent litigation trends: the future of biologics and next generation therapies

Biologics and biosimilars are an emerging patent battleground across the globe, with significant litigation, particularly in the US, making regular headlines. 

Life Sciences IP Review has partnered with international law firm Gowling WLG to survey those at the sharp edge of this industry, in an attempt to understand what’s happening, and to help you gain a sense of how it is likely to develop in the future.

Download the full report by entering your details on the right >>

With responses from across private practice and in-house counsel active in biosimilar litigation, it provides an intriguing snapshot of current sentiment, and food for thought as to how strategies may need to adapt in the future.

The report also includes a coda on the broader picture for next generation therapies— those technologies that will likely dictate what happens in the longer term—to help you identify where your next patent challenges will occur.

Download your copy now by entering your details in the form on the right >>

For more information, contact:

Peter Scott
Group Publisher
Tel: +44 203 301 8217

Download your report here!

Enter your details below and you’ll immediately receive a copy of the report straight to your inbox.

This special report is produced by Life Sciences IP Review and sponsored by Gowling WLG. By registering to view the publication, you agree to share your contact information with both Life Sciences IP Review and Gowling WLG. Full details of our privacy policy can be found here .

Sponsored by